GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Pulmonx Corp (NAS:LUNG) » Definitions » PB Ratio
中文

Pulmonx (Pulmonx) PB Ratio : 2.45 (As of Apr. 25, 2024)


View and export this data going back to 2020. Start your Free Trial

What is Pulmonx PB Ratio?

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2024-04-25), Pulmonx's share price is $7.52. Pulmonx's Book Value per Share for the quarter that ended in Dec. 2023 was $3.07. Hence, Pulmonx's PB Ratio of today is 2.45.

Good Sign:

Pulmonx Corp stock PB Ratio (=2.44) is close to 1-year low of 2.43

The historical rank and industry rank for Pulmonx's PB Ratio or its related term are showing as below:

LUNG' s PB Ratio Range Over the Past 10 Years
Min: 1.1   Med: 3.88   Max: 10.9
Current: 2.45

During the past 6 years, Pulmonx's highest PB Ratio was 10.90. The lowest was 1.10. And the median was 3.88.

LUNG's PB Ratio is ranked worse than
54.77% of 796 companies
in the Medical Devices & Instruments industry
Industry Median: 2.2 vs LUNG: 2.45

During the past 12 months, Pulmonx's average Book Value Per Share Growth Rate was -25.10% per year. During the past 3 years, the average Book Value Per Share Growth Rate was -21.40% per year.

During the past 6 years, the highest 3-Year average Book Value Per Share Growth Rate of Pulmonx was -21.40% per year. The lowest was -21.40% per year. And the median was -21.40% per year.

Back to Basics: PB Ratio


Pulmonx PB Ratio Historical Data

The historical data trend for Pulmonx's PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pulmonx PB Ratio Chart

Pulmonx Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
PB Ratio
Get a 7-Day Free Trial - 10.90 6.13 2.06 4.15

Pulmonx Quarterly Data
Dec18 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.06 2.93 3.72 3.15 4.15

Competitive Comparison of Pulmonx's PB Ratio

For the Medical Devices subindustry, Pulmonx's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Pulmonx's PB Ratio Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Pulmonx's PB Ratio distribution charts can be found below:

* The bar in red indicates where Pulmonx's PB Ratio falls into.



Pulmonx PB Ratio Calculation

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.

Pulmonx's PB Ratio for today is calculated as follows:

PB Ratio=Share Price/Book Value per Share (Q: Dec. 2023)
=7.52/3.072
=2.45

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.


Pulmonx  (NAS:LUNG) PB Ratio Explanation

Unlike valuation ratios relative to the earning power such as PE Ratio, PE Ratio without NRI, PS Ratio, Price-to-Operating-Cash-Flow , or Price-to-Free-Cash-Flow, the PB Ratio measures the valuation of the stock relative to the underlying asset of the company.

The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.


Pulmonx PB Ratio Related Terms

Thank you for viewing the detailed overview of Pulmonx's PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Pulmonx (Pulmonx) Business Description

Traded in Other Exchanges
Address
700 Chesapeake Drive, Redwood, CA, USA, 94063
Pulmonx Corp is a commercial-stage medical technology company. It provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). the company's solutions comprised of the Zephyr Endobronchial Valve, the Chartis Pulmonary Assessment System and the StratX Lung Analysis Platform. It generates revenue through the sale of products to distributors and hospitals in the U.S. and international markets.
Executives
French Glendon E. Iii director, officer: President and CEO 700 CHESAPEAKE DRIVE, REDWOOD CITY CA 94063
Geoffrey Beran Rose officer: Chief Commercial Officer 5124 ROCKWOOD PARKWAY NW, WASHINGTON DC 20016
John Mckune officer: Interim CFO 46668 CRAWFORD CT., FREMONT CA 94539
David Aaron Lehman officer: General Counsel C/O INTERSECT ENT, INC., 1555 ADAMS DRIVE, MENLO PARK CA 94025
Derrick Sung officer: Chief Financial Officer C/O IRHYTHM TECHNOLOGIES, INC., 650 TOWNSEND STREET, SUITE 380, SAN FRANCISCO CA 94103
Alissa Hsu Lynch director 700 CHESAPEAKE DRIVE, REDWOOD CITY CA 94063
Richard M Ferrari director 2118 WALSH AVENUE, SUITE 210, SANTA CLARA CA 95050
Tiffany Sullivan director 700 CHESAPEAKE DRIVE, REDWOOD CITY CA 94063
Boston Scientific Corp 10 percent owner 300 BOSTON SCIENTIFIC WAY, MARLBOROUGH MA 01752-1234
Daniel P Florin director 56 E. BELL DRIVE, WARSAW IN 46581
Mead Dana G Jr. director 2750 SAND HILL ROAD, MENLO PARK CA 94025
Thomas William Burns director C/O GLAUKOS CORPORATION,, 26051 MERIT CIRCLE, SUITE 103, LAGUNA HILLS CA 92653
Georgia Melenikiotou director C/O INSPIRE MEDICAL SYSTEMS, INC., 5500 WAYZATA BOULEVARD, SUITE 1600, GOLDEN VALLEY MN 55416
Staffan Lindstrand director C/O ODLANDER, FREDRIKSON & CO. AB, STRANDVAGEN 5B, STOCKHOLM V7 SE-114 51

Pulmonx (Pulmonx) Headlines